HER-2 pulsed DC1
Phase 2Biologic
HER-2 pulsed DC1 is one of 6 biologic programs targeting Dendritic Cell. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
5 competitors in Dendritic Cell
#DrugCompanyPhaseTrials
1Perjeta
RochePhase 2
Taxol
TevaPhase 2
Herceptin
OOrganon and Co
Phase 2
Interleukin 2
EEssen Biotech
Phase 2
HER-2 pulsed DC1
HH. Lee Moffitt Cancer Center and Research Institute
Phase 2
Allogenic Dendritic Cells
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HER-2 pulsed DC1. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details